BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8141109)

  • 1. Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer.
    Blumenreich MS; Sheth SP; Miller CL; Farnsley ES; Kellihan MJ; Joseph UG; Hamm JT; Seeger J; Robinson LH; Hagan PC
    Am J Clin Oncol; 1994 Apr; 17(2):163-5. PubMed ID: 8141109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
    Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
    J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum/oral etoposide therapy in non-small cell lung cancer.
    Furuse K
    Oncology; 1992; 49 Suppl 1():63-9; discussion 70. PubMed ID: 1323814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic oral etoposide in non-small cell lung carcinoma.
    Estapé J; Palombo H; Sánchez-Lloret J; Agustí C; Grau JJ; Daniels M; Viñolas N; Solá C; Biete A; Ramirez J
    Eur J Cancer; 1992; 28A(4-5):835-7. PubMed ID: 1326308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral UFT, etoposide and leucovorin in recurrent non-small cell lung cancer: a non-randomized phase II study.
    Surmont V; Aerts JG; Pouw E; Tan KY; Vernhout R; Gras J; Salomé J; Pronk T; Schmitz PI; Hoogsteden H; van Klaveren RJ
    Lung Cancer; 2009 Dec; 66(3):333-7. PubMed ID: 19327865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.
    Pujol JL; Lafontaine T; Quantin X; Reme-Saumon M; Cupissol D; Khial F; Michel FB
    Chest; 1999 Jan; 115(1):144-50. PubMed ID: 9925076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
    Grunberg SM; Crowley J; Livingston R; Gill I; Williamson SK; O'Rourke T; Braun T; Marshall ME; Weick JK; Balcerzak SP
    J Clin Oncol; 1993 Aug; 11(8):1598-601. PubMed ID: 8393099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study.
    Gridelli C; Rossi A; Scognamiglio F; Guida C; Fiore F; Gatani T; Scoppa G; Pergola M
    Anticancer Res; 1997; 17(6D):4755-8. PubMed ID: 9494602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.
    Saxman S; Loehrer PJ; Logie K; Stephens D; Workman F; Scullin D; Einhorn LH; Ansari R
    Invest New Drugs; 1991 Aug; 9(3):253-6. PubMed ID: 1664423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of daily administration of oral etoposide for non-small cell lung cancer treated with concurrent radiation therapy].
    Ohnishi H; Okada J; Yamaguchi M; Ogata H; Hatano K; Takizawa Y; Imai Y; Hara R; Araki T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1997 Jul; 57(8):510-4. PubMed ID: 9267140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination chemotherapy with oral etoposide.
    Johnson DH; Hainsworth JD; Hande KR; Greco FA
    Semin Oncol; 1992 Dec; 19(6 Suppl 14):19-24. PubMed ID: 1336896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia.
    Frasci G; Comella P; Panza N; De Cataldis G; Del Gaizo F; Pozzo C; Gravina A; Ruffolo P; Cioffi R; Marcatili P; Della Vittoria M; Monfardini S; Comella G
    Eur J Cancer; 1998 Oct; 34(11):1710-4. PubMed ID: 9893657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.
    Johnson DH; DeVore R; Greco FA; Walls J; Thomas M; Hande KR; Hainsworth JD
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):50-6. PubMed ID: 1329223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prolonged oral etoposide therapy in advanced stage lung cancer].
    Bozóky G; Ruby E; Góhér I; Mohos A; Lengyel M
    Orv Hetil; 1997 Jul; 138(28):1791-5. PubMed ID: 9280873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-term oral administration of etoposide in the treatment of patients with advanced non-small-cell carcinoma of the lung. The second phase of a clinical study].
    Jeremić B; Djurić Lj; Jevremović S; Stefanović K; Matović M
    Srp Arh Celok Lek; 1996; 124(3-4):65-8. PubMed ID: 9102821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
    Hirabayashi M; Tanaka Y; Yoshida H; Nakagawa M; Kuno K
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):53-8. PubMed ID: 8291916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06.
    Lee JS; Scott C; Komaki R; Fossella FV; Dundas GS; McDonald S; Byhardt RW; Curran WJ
    J Clin Oncol; 1996 Apr; 14(4):1055-64. PubMed ID: 8648357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
    Einhorn LH; Pennington K; McClean J
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):32-5. PubMed ID: 2154857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.